GGrantIndex
← Search

Cancer Prevention and Control Program - 05

$36,868P30FY2017CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Trial NCT02989636Trial NCT02516670Trial NCT02491411Trial NCT02489357Trial NCT02029950Trial NCT01935947Trial NCT01870596Trial NCT01783171Trial NCT01757639Trial NCT01578109Trial NCT01349972Trial NCT01349959Trial NCT01330173Trial NCT01264432Trial NCT01207726Trial NCT01207687Trial NCT01139970Trial NCT01132573Trial NCT01061749Trial NCT00971737Trial NCT00963807Trial NCT00899951Trial NCT00899548Trial NCT00898482Trial NCT00897338Trial NCT00897273Trial NCT00847171Trial NCT00795002Trial NCT00727441Trial NCT00673569Trial NCT00670917Trial NCT00660348Trial NCT00641303Trial NCT00641147Trial NCT00631137Trial NCT00616967Trial NCT00602771Trial NCT00588991Trial NCT00566098Trial NCT00524017Trial NCT00499733Trial NCT00499486Trial NCT00493025Trial NCT00492921Trial NCT00489281Trial NCT00478062Trial NCT00478010Trial NCT00471653Trial NCT00470093Trial NCT00469820Trial NCT00445484Trial NCT00433472Trial NCT00425477Trial NCT00407966Trial NCT00401024Trial NCT00389610Trial NCT00387465Trial NCT00381550Trial NCT00373191Trial NCT00369681Trial NCT00368914Trial NCT00363649Trial NCT00361296Trial NCT00356928Trial NCT00354640Trial NCT00343447Trial NCT00336063Trial NCT00334542Trial NCT00324870Trial NCT00313560Trial NCT00311623Trial NCT00305760Trial NCT00303927Trial NCT00293410Trial NCT00293397Trial NCT00293280Trial NCT00290732Trial NCT00287989Trial NCT00287872Trial NCT00281970Trial NCT00281866Trial NCT00278200Trial NCT00278161Trial NCT00278109Trial NCT00276744Trial NCT00276601Trial NCT00276588Trial NCT00274768Trial NCT00265915Trial NCT00265837Trial NCT00262834Trial NCT00258206Trial NCT00258180Trial NCT00255775Trial NCT00255710Trial NCT00245115Trial NCT00244959Trial NCT00242996Trial NCT00238368Trial NCT00238277

Abstract

ABSTRACT Effective cancer prevention and control requires a better understanding of the causes and risk factors for cancer as well as the development and testing of strategies to prevent cancer and improve the quality of cancer care. The mission of the Cancer Prevention and Control (CPC) Program of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) is to conduct population-focused, multidisciplinary and translational cancer research, with the goal of developing preventive measures. These include early detection approaches and interventions needed to reduce cancer incidence, recurrence/progression and related deaths as well as improving health-related quality of life and care of cancer patients. Program research is organized around three research themes with the following aims: Aim 1: Cancer Epidemiology: To identify causes of cancer occurrence in at-risk populations and poor objective outcomes in cancer patients using epidemiologic methods. Aim 2: Viral Oncology: To understand the role of viruses in cancer, specifically human papillomavirus (HPV), human herpesvirus-8 (HHV-8), human T-lymphotropic virus 1 (HTLV-1) and hepatitis B virus (HBV), and the mechanisms and biomarkers of this oncogenesis as the basis for developing preventive, diagnostic and therapeutic strategies. Aim 3: Patient-Centered Outcomes and Palliative Care Research: To assess and determine how to improve patient-reported outcomes and the quality of care services, including palliative care. The CPC Program's portfolio of research addresses the causes of cancer and spans the cancer control continuum, from prevention to survivorship and end of life. The Program facilitates Intra- and Inter- Programmatic population-based, translationally focused research on cancer, including team science. It recruits and mentors new investigators whose research is compatible with its mission; coordinates seminars and other venues for information exchange on cutting-edge, population-focused research and methods; participates in state and local public health efforts to translate knowledge learned into improved practice; and generates knowledge informing cancer care across the cancer control continuum in the health system, the catchment area, nationally and globally. The Program benefits from the Maryland Cigarette Restitution Fund (CRF) at Johns Hopkins (2001?present) through support for new faculty recruitments and population-focused translational research pilot projects. The SKCCC, and particularly the CPC Program, is fully engaged in the Maryland state government's comprehensive cancer control planning and implementation and the Maryland State Council on Cancer Control. The CPC Program includes 36 members from 14 departments and three schools, and two members-in-development. NCI and other peer-reviewed support of Program members totals $18.4 million total costs. Program members have 707 publications?101 (14%) are Intra-Programmatic, 291 (41%) are Inter-Programmatic and 355 (50%) publications represent multi-institutional collaborations. The members are guiding future directions, including translation of Program findings into proof-of-principle intervention trials in the community and health care system, and strengthening collaborations with Johns Hopkins Community Physicians. The Program continues to conduct research aimed at eliminating disparities in the Johns Hopkins catchment area, with a focus on prostate, breast, colorectal and HPV-related cancers.

View original record on NIH RePORTER →